comparemela.com
4
5
6
7
8
9
10
Latest Breaking News On - Douglas hanahan - Page 3 : comparemela.com
Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers
Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.
Switzerland
Swiss
Douglas-hanahan
Emily-henderson
Swiss-institute-for-experimental-cancer-research
Lausanne-university-hospital
Ludwig-institute-for-cancer-research
Swiss-institute-for-bioinformatics
Experimental-cancer-research
Ludwig-institute
Cancer-research
Swiss-institute
FogPharma's $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
Northpond
Massachusetts
United-states
Wellington
New-zealand-general
New-zealand
Munich
Bayern
Germany
California
Indiana
Cambridge
Opna Bio Raises $38M in Series A Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Epalinges
Switzerland-general
Switzerland
Israel
San-francisco
California
United-states
Inozyme-pharma
Robert-darnell
Berta-strulovici
Benjamin-cravatt
Opna-bio
Study suggests protein plays a key role in immunotherapy
By using the patient s own immune system against the tumour, immunotherapy is a cutting-edge method of treating cancer
Switzerland
Swiss
Douglas-hanahan
Opna-bio
Swiss-institute-for-experimental-cancer-research
University-hospital-of-lausanne
Swiss-institute
Experimental-cancer-research
Lausanne-branch
Ludwig-institute
Cancer-research
University-hospital
Cancer drugmaker Plexxikon gets new life as Opna Bio
BioPharma
Japan
Switzerland
Japanese
Swiss
Douglas-hanahan
Daiichi-sankyo
Joseph-schlessinger
Opna-bio
Gideon-bollag
Drug-administration
Swiss-federal-institute-of-technology-lausanne
South-san
vimarsana © 2020. All Rights Reserved.